Targeting Microbiota 2020 will be a Virtual and In-Person Congress

We have been closely following updates and evolving guidance from local, national and global agencies for COVID-19. There is still much uncertainty around the coronavirus, and how long our communities may be impacted by the pandemic, but it seems certain that decisions about how we work, travel and gather together will continue to be influenced for weeks and months still to come. Today, we have made the decision to combine In-Person and Virtual conference.


If you cannot attend in-person or virtual due to the restriction and time zone difference, you can access on-demand videos to this entire event, including synced audio/video and slides.

All posters will be in PDF format. You can visit them, upload and interact directly with the poster presenter. You can also exchange with speakers via direct or private exchange during the conference.

We will keep you informed of any new decision.

Welcome to Targeting Microbiota 2020

President Targeting Microbiota 2020Dear colleagues,

On behalf of the International Society of Microbiota, we are pleased to inform you that the 8th World Congress on Targeting Microbiota will be organized at UNESCO World Heritage Centre - Paris, France, on
October 21-23, 2020. 


Gut microbiota and graft-versus-host disease in patients after bone marrow transplantation. FMT as a prevention or treatment?

Jarosław Bilinski Targeting Microbiota 2019

Dr. Jaroslaw Bilinski from Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Poland will join the 7th World Congress of Targeting Microbiota which will be held in Krakow, Poland on October 10-11, 2019.
During the meeting Dr. Bilinski will give a presentation entitled "Gut microbiota and graft-versus-host disease in patients after bone marrow transplantation. FMT as a prevention or treatment?".
Gut dysbiosis is considered as trigger or cause of many diseases including graft-versus-host disease (GvHD), a life threatening complication that occurs after allogeneic hematopoietic cell transplantation (alloHCT) caused by an allogeneic attack of donor T cells against recipient tissues. Gut GvHD is the most difficult to treat and linked with high mortality. There are novel insights to immune system interplaying with microbiota which we may use and try to modulate microbiota to prevent or treat GvHD. The question is when and what to do, as the process of immune stimulation is very fluent.

For more information:

Microbiota World Congress 2019

bouton more pictures

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next